 |
|
Customized treatments for sepsis lower treatment time and reduce length of ICU stays
February 29, 2008Using a blood test and a decision algorithm, rather than standard hospital protocols, to determine the appropriate length of antibiotic therapy in patients with severe sepsis or septic shock can reduce duration of treatments, shorten ICU stays, and lower hospital costs- all without adverse effects on patients, according to new research.
"We have shown that it is possible to customize antibiotic treatment duration in patients with septicemia based on a reliable and robust blood test," says Jérôme Pugin, M.D., of the Intensive Care Unit at the University Hospital in Geneva, Switzerland.
The findings appear in the first issue for March of the American Journal of Respiratory and Clinical Care Medicine, published by the American Thoracic Society.
The researchers randomized 79 patients to receive a treatment course of antibiotics either according standard treatment protocols administered by the treating physicians, or according to the decision algorithm based on measured blood levels of procalcitonin (PCT), a marker for severe bacterial infection in patients with suspected sepsis. For patients randomized to the PCT-based treatment there were predetermined "stopping rules" based on circulating PCT levels at which point investigators encouraged treating physicians to discontinue antibiotic therapy, although the treating physician retained the ultimate decision-making power.
In the analysis that included all 79 patients, the median treatment time for the PCT group was 3.5 fewer days than that of the control group, although the difference was not significant. However, once the investigators controlled for early drop-outs, previously undiagnosed infections, and patients whose physicians declined to stop antibiotic treatment when the algorithm would have dictated it, they found that patients treated by the PCT algorithm had a significantly shorter treatment time at 6 days, than patients treated according to standard protocols, who averaged 12.5 days on antibiotics.
"Our study is the first randomized clinical trial in which a surrogate biochemical parameter was used to reduce the duration of antibiotic therapy in a population of critically ill patients admitted to the ICU for severe sepsis and septic shock," wrote Dr. Pugin. "Despite the relatively short duration of treatment in bacteremic patients assigned to the PCT group, no case of recurrence of infection was observed in these patients."
Following the PCT algorithm had another benefit: patients randomized to the PCT treatment had significantly shorter stays in the ICU than control patients-an average of three days versus five.
Customizing treatment does more than simply save hospitals money and patients precious days in the ICU, says Dr. Pugin. Overuse of antibiotics can result in antibiotic resistance. "Given the diversity of the types of infections, bacterial strains and levels of host immune defense, every infected patient should benefit from a personalized treatment, and particularly, a personalized treatment duration," he said.
The investigators hope that customized treatments will continue to improve care for sepsis patients around the world. "We have now implemented this new algorithm based on procalcitonin guidance in our ICU for patients presenting with severe sepsis and septic shock, and are following the outcome of those patients," said Dr. Pugin. "Currently, three large multi-center trials are ongoing in France, Denmark and Germany, with a design similar to that of our study. Results from these studies will be important to determine whether such a protocol of procalcitonin guidance is definitely safe and can be generalized worldwide."
American Thoracic Society
The researchers randomized 79 patients to receive a treatment course of antibiotics either according standard treatment protocols administered by the treating physicians, or according to the decision algorithm based on measured blood levels of procalcitonin (PCT), a marker for severe bacterial infection in patients with suspected sepsis. For patients randomized to the PCT-based treatment there were predetermined "stopping rules" based on circulating PCT levels at which point investigators encouraged treating physicians to discontinue antibiotic therapy, although the treating physician retained the ultimate decision-making power.
In the analysis that included all 79 patients, the median treatment time for the PCT group was 3.5 fewer days than that of the control group, although the difference was not significant. However, once the investigators controlled for early drop-outs, previously undiagnosed infections, and patients whose physicians declined to stop antibiotic treatment when the algorithm would have dictated it, they found that patients treated by the PCT algorithm had a significantly shorter treatment time at 6 days, than patients treated according to standard protocols, who averaged 12.5 days on antibiotics.
"Our study is the first randomized clinical trial in which a surrogate biochemical parameter was used to reduce the duration of antibiotic therapy in a population of critically ill patients admitted to the ICU for severe sepsis and septic shock," wrote Dr. Pugin. "Despite the relatively short duration of treatment in bacteremic patients assigned to the PCT group, no case of recurrence of infection was observed in these patients."
Following the PCT algorithm had another benefit: patients randomized to the PCT treatment had significantly shorter stays in the ICU than control patients-an average of three days versus five.
Customizing treatment does more than simply save hospitals money and patients precious days in the ICU, says Dr. Pugin. Overuse of antibiotics can result in antibiotic resistance. "Given the diversity of the types of infections, bacterial strains and levels of host immune defense, every infected patient should benefit from a personalized treatment, and particularly, a personalized treatment duration," he said.
The investigators hope that customized treatments will continue to improve care for sepsis patients around the world. "We have now implemented this new algorithm based on procalcitonin guidance in our ICU for patients presenting with severe sepsis and septic shock, and are following the outcome of those patients," said Dr. Pugin. "Currently, three large multi-center trials are ongoing in France, Denmark and Germany, with a design similar to that of our study. Results from these studies will be important to determine whether such a protocol of procalcitonin guidance is definitely safe and can be generalized worldwide."
American Thoracic Society
Sepsis Current Events and Sepsis News RSSA Second Skin
Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections.
Progress made on group B streptococcus vaccine
Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible.
Canadian scientists link fat hormone to death from potentially deadly blood infection
A new Canadian study has found that lower-than-normal levels of a naturally-occurring fat hormone may increase the risk of death from sepsis-an overwhelming infection of the blood which claims thousands of lives each year.
OMRF scientists discover promising new path for treating traumas
A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.
Scientists create NICE solution to pneumonia vaccine testing problems
Medical clinics the world over could benefit from new software* created at the National Institute of Standards and Technology (NIST), where a team of scientists has found a way to improve the efficiency of a pneumonia vaccine testing method developed at the University of Alabama at Birmingham (UAB).
Compound shows potential for slowing progression of ALS
A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice.
Review: Pneumococcal conjugate vaccines effective at preventing child deaths
A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths.
Key feature of immune system survived in humans, other primates for 60 million years
A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.
Discovery may lead to powerful new therapy for asthma
University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.
Abnormal Brain Circuits May Prevent Movement Disorder
Most people who carry a genetic mutation for a movement disorder called dystonia will never develop symptoms, a phenomenon that has puzzled scientists since the first genetic mutation was identified in the 1990's.
More Sepsis Current Events and Sepsis News Articles
 |
Sepsis: New Strategies for Management by Jordi Rello (Editor), Marcos I. Restrepo (Editor) Sepsis is an important public health problem around the world. Severe sepsis carries significant morbidity, mortality and high costs. The incidence of sepsis is increasing because of the aging population, the growing number of immunocompromised hosts, the increasing use of invasive procedures, and, to a lesser extent, antibiotic resistance among pathogens. Despite recent advances in the pathogenesis, diagnosis, and therapeutic approaches the mortality rate associated with this condition remains high. Therefore, the goal of Sepsis: New Strategies is to review novel targets to be considered in patients with severe sepsis and to assess new developments for patients with sepsis originating in the respiratory tract. |
 |
Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery (Update in Intensive Care Medicine) by Edward Abraham (Editor), Mervyn Singer (Editor) There have been tremendous advances in understanding the cellular mechanisms involved in sepsis and contributing to the development of multiple organ dysfunction and mortality in this setting. The chapters in this book provide up-to-date insights into important pathways that are initiated by sepsis. |
 |
Sepsis and Non-infectious Systemic Inflammation: From Biology to Critical Care by Jean-Marc Cavaillon (Editor), Christophe Adrie (Editor) Providing definitions, clinical features and epidemiology, Sepsis and Non-infectious Systemic Inflammation adopts a comprehensive approach, describing in detail the various physiological systems involved. As such, this unique handbook and reference work is the first to combine sepsis and non-infectious SIRS, reviewing both the biological and medical aspects of these two important syndromes. The whole is rounded off with a discussion of past, present and future therapies. |
 |
Deep Sea Creatures by Monstrum Sepsis Monstrum Sepsis (Performer) Monstrum Sepsis emerges from the depths to bring you a new full length album of exquisitely inspired and arranged electronic music. Written and composed by Rob Wentz with additional instrumentation from Paul Karlik and guest vocals from Shikhee of Android Lust. Originally limited to 300 copies this new pressing features a few artwork enhancements as well as two new tracks. These 12 tracks will lift you off your feet in a sonic array of pulsing synthetics, disruptive modulations, sweeping strings and incredibly infectious rhythms. |
 |
Primordial Notions Delta 2001-2004 Monstrum Sepsis (Primary Contributor) |
|
Bacteria Sepsis: Video 1 of 3 [VHS] Starring: Diane Charsha | |
 |
Management of Sepsis: the PIRO Approach by Jordi Rello (Editor), Emili Díaz (Editor), Alejandro Rodríguez (Editor) Sepsis is a very important public health problem. It is widely acknowledged that the severe inflammatory response syndrome/severe sepsis paradigm fails to stratify sepsis patients adequately. This book reviews in detail how sepsis should be managed on the basis of a novel approach to staging. The PIRO (predisposing factors, infection, response, organ dysfunction) model was first proposed at the start of the decade on a theoretical basis and has now been translated into a practical approach for use at the bedside. It is loosely based on the TNM staging system for cancers, with points being allocated to each of the four aforementioned key characteristics of the septic process. The proposed PIRO framework facilitates evaluation of factors that are important in the pathogenesis of severe... |
 |
Sepsis (Competency-Based Critical Care) by Simon V. Baudouin (Editor) Sepsis is a serious medical condition, resulting from the immune response to a severe infection. Septicaemia is sepsis of the bloodstream caused by bactemeria, which is the presence of bacteria in the bloodstream. The term septecaemia is also used to refer to sepsis in general. In the US, sepsis is the leading cause of death in non-coronary ICU patients, and the tenth most common form of death overall. Sepsis is common and also more dangerous in the elderly, immunocompromised, and critically ill patients. It occurs in 1-2% of all hospitilizations and accounts for as much as 25% of all ICU bed utilization. It is a major cause of death in intensive care units worldwide, with mortality rates that range from 20% for sepsis to 40% for severe sepsis to more than 60% for septic shock. The... |
 |
Impact 1.5 250 ml Cans, 24/cs (202.8 oz/cs) by Novartis IMPACT 1.5 is a calorically dense, patented enteral formula containing arginine, dietary nucleotides and fish oil. Each member of the Impact family of products has a unique and patented formula that has been demonstrated in clinical trials to improve patient outcomes. Specifically, patients who received an Impact formula in clinical trials developed fewer infections and had shorter hospital stays than those patients fed enteral formulas. Impact 1.5 formula is intended for patients with fluid restrictions or high energy needs. Impact 1.5 is a Medical Food- consumers should consult with their physician on the use of this product. 250 ml Cans, 24/Case (202.8 oz/Case) Provides nutritional support for immuno compromised patients who require fluid restriction or have higher energy needs such... |
 |
Primordial Notions Gamma 1996-2000 Monstrum Sepsis (Primary Contributor) |
| © 2009 BrightSurf.com |